<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04255823</url>
  </required_header>
  <id_info>
    <org_study_id>RC19_0460</org_study_id>
    <nct_id>NCT04255823</nct_id>
  </id_info>
  <brief_title>Efficacy of a Multi-faceted Intervention to Deprescribe Proton Pump Inhibitors (PPI) in Primary Care: a Population-based, Pragmatic, Cluster-randomized Controlled Trial.</brief_title>
  <acronym>DeprescrIPP</acronym>
  <official_title>Efficacy of a Multi-faceted Intervention to Deprescribe Proton Pump Inhibitors (PPI) in Primary Care: a Population-based, Pragmatic, Cluster-randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Deprescribing is defined as &quot;the process of withdrawal of an inappropriate medication,
      supervised by a health care professional with the goal of managing the polypharmacy and
      improving outcomes&quot;. Inappropriate use of proton pump inhibitors (PPI) is associated with
      severe adverse drug reactions and a major economic impact. Deprescribing should be considered
      when inappropriate prescription of PPI is identified.

      DeprescrIPP is a pragmatic population-based cluster-randomized trial conducted in primary
      care. It will assess the efficacy and effectiveness of a multi-faceted intervention (on
      patients and general practitioners) to deprescribe PPI.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PPI deprescribing</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of patients achieving a 50% decrease in their reimbursement of PPI (Defined Daily Dose (DDD)/year) at the end of the intervention compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost-utility analysis</measure>
    <time_frame>12 months</time_frame>
    <description>Incremental cost-utility ratio (cost by quality-adjusted life-years, QALY) of control group compared to the intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GERD symptoms recurrence</measure>
    <time_frame>12 months</time_frame>
    <description>A short-form REFLUX-QUAL questionnaire will be assessed to a 10% patient sample in each arm (baseline and 12 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attitudes of patients towards deprescribing</measure>
    <time_frame>12 months</time_frame>
    <description>Revised patients' attitudes toward deprescribing questionnaire will be assigned to a 10% patient sample in each arm (baseline and 12 months)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">34000</enrollment>
  <condition>Proton Pump Inhibitors</condition>
  <condition>Deprescription</condition>
  <arm_group>
    <arm_group_label>Multi-faceted intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A patient education material on PPI deprescribing will be send to patients with long-term treatment with PPI (&gt;300DDD/patient/year).
Their general practitioner (GP) will receive a &quot;dear doctor&quot; letter with an algorithm related to PPI deprescribing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;Dear doctor&quot; letter of the GP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Only the GP will receive the &quot;dear doctor&quot; letter with the algorithm.
Their patients will not receive any patient education material.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Neither the patients nor their GP will receive information.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>General practitioner and Patient receive informations related to PPI deprescribing.</intervention_name>
    <description>General practitioner will receive a sensibilization and an algorithm related to PPI deprescribing.
Their patients will receive any informations (patient information material on PPI deprescribing)</description>
    <arm_group_label>Multi-faceted intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Only General practitioner receive informations related to PPI deprescribing.</intervention_name>
    <description>General practitioner will receive the sensibilization and an algorithm related to PPI deprescribing.
Their patients will not receive any informations.</description>
    <arm_group_label>&quot;Dear doctor&quot; letter of the GP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  General practitioners (GPs):

             • All GPs settled in the 2 departments of Loire-Atlantique and Vendée with more than
             100 patients in the year before baseline, will be eligible.

          -  Patients:

               -  aged over 18 years

               -  affiliated to the French health insurance system (CPAM)

               -  treated with PPI with more than 300 DDD/year in the year before baseline,
                  estimated with reimbursement databases.

               -  whose GP is included in the study

        Exclusion Criteria:

          -  General practitioners (GPs):

             • Participation refusal

          -  Patients :

               -  Participation refusal

               -  Patients aged &gt;65 or with corticosteroids/anticoagulants and NSAIDs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Pascal FOURNIER, Doctor</last_name>
    <phone>02.40.41.28.28</phone>
    <email>jean-pascal.fournier@univ-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jérôme NGUYEN</last_name>
    <phone>02.40.41.28.28</phone>
    <email>jerome.nguyen-soenen@univ-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 3, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Proton pump inhibitors</keyword>
  <keyword>Deprescription</keyword>
  <keyword>Multi-faceted intervention</keyword>
  <keyword>Patient-centered</keyword>
  <keyword>Primary health care</keyword>
  <keyword>Pharmacoepidemiology</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

